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Abstract
Background: Rheumatic fever continues to put a significant burden on the health of low socio-
economic populations in low and middle-income countries despite the near disappearance of the
disease in the developed world over the past century. Antibiotics have long been thought of as an
effective method for preventing the onset of acute rheumatic fever following a Group-A
streptococcal (GAS) throat infection; however, their use has not been widely adopted in
developing countries for the treatment of sore throats. We have used the tools of systematic
review and meta-analysis to quantify the effectiveness of antibiotic treatment for sore throat, with
symptoms suggestive of group A streptococcal (GAS) infection, for the primary prevention of acute
rheumatic fever.
Methods: Trials were identified through a systematic search of titles and abstracts found in the
Cochrane Central Register of Controlled Trials (Cochrane Library Issue 4, 2003), MEDLINE
(1966–2003), EMBASE (1966–2003), and the reference lists of identified studies. The selection
criteria included randomised or quasi-randomised controlled trials comparing the effectiveness of
antibiotics versus no antibiotics for the prevention of rheumatic fever in patients presenting with a
sore throat, with or without confirmation of GAS infection, and no history of rheumatic fever.
Results: Ten trials (n = 7665) were eligible for inclusion in this review. The methodological quality
of the studies, in general, was poor. All of the included trials were conducted during the period of
1950 and 1961 and in 8 of the 10 trials the study population consisted of young adult males living
on United States military bases. Fixed effects, meta-analysis revealed an overall protective effect for
the use of antibiotics against acute rheumatic fever of 70% (RR = 0.32; 95% CI = 0.21–0.48). The
absolute risk reduction was 1.67% with an NNT of 53. When meta-analysis was restricted to
include only trials evaluating penicillin, a protective effect of 80% was found (Fixed effect RR = 0.20,
95% CI = 0.11–0.36) with an NNT of 60. The marginal cost of preventing one case of rheumatic
fever by a single intramuscular injection of penicillin is approximately US$46 in South Africa.
Conclusion: Antibiotics appear to be effective in reducing the incidence of acute rheumatic fever
following an episode of suspected GAS pharyngitis. This effect may be achieved at relatively low
cost if a single intramuscular penicillin injection is administered.
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Background
Rheumatic fever is the most common cause of acquired
heart disease in children and adults worldwide [1,2].
Acute rheumatic fever is expressed as an inflammatory
reaction that involves many organs, primarily the heart,
the joints, and the central nervous system [3]. The clinical
manifestations of acute rheumatic fever follow a group A
streptococcal (GAS) infection of the tonsillopharynx after
a latent period of approximately 3 weeks. The major
importance of acute rheumatic fever is its ability to cause
fibrosis of heart valves, leading to crippling hemodynam-
ics of chronic heart disease, heart failure and death. Open
heart surgery may be needed to repair or replace heart
valves in patients with severely damaged valves, the cost of
which is exorbitant and a drain on the limited health
resources of poor countries [4,5].
The global burden of disease caused by rheumatic fever
currently falls disproportionately on children living in the
developing world. Rheumatic heart valve disease causes
400,000 deaths annually mainly among children and
young adults living in developing countries. At least 12
million people are estimated to be currently affected by
rheumatic heart disease with two million patients requir-
ing repeated hospitalisation and one million requiring,
often unaffordable, heart surgery in the next 5 to 20 years
[6]. In many developing countries, the incidence of acute
rheumatic fever approaches or exceeds 100 per 100,000,
whereas the incidence is currently estimated at less than 2
per 100,000 in the US.[1,2] This decline of rheumatic
fever in the industrialised world has been partially attrib-
uted to the use of antibiotics for the treatment of GAS
infections [7], but it is also believed to be the result of
improved living conditions [8]. However, the recent resur-
gence of rheumatic fever in middle-class families in some
parts of the economically developed world is a reminder
that even in industrialised countries, there is no room for
complacency [9,10].
The bulk of the research on the prevention of rheumatic
fever dates back to the mid-20th century and was con-
ducted primarily on adult populations living in the
United States [11]. Methods for preventing rheumatic
heart disease have included both primary and secondary
prevention strategies. Primary prevention is achieved by
disrupting the initial transmission of GAS infection or by
blocking the progression of GAS infection to rheumatic
fever. Secondary prevention is used following an attack of
acute rheumatic fever to prevent the progression to cardiac
disease. The consensus reached in the 1950's was that the
most effective and efficient method for preventing rheu-
matic heart disease was through the primary prevention of
acute rheumatic fever using antibiotics to treat the preced-
ing GAS infection (WHO 1954) [12]. Where primary pre-
vention failed, a secondary prevention plan also relying
on antibiotic therapy was recommended for preventing
the progression of cardiovascular complications [13].
Treatment of streptococcal pharyngitis with antibiotics is
currently standard practice in most of the developed
world. To note some exceptions, there are a few countries
that now recommend no investigation or treatment of
sore throat based on recent fears of increasing antibiotic
resistance compounded with the findings of a recent study
highlighting the negligible benefits gained from antibiotic
treatment [14]. This new rationale for treating sore throat
with antibiotics may not be applicable to a developing
country setting where there remains a real threat of rheu-
matic fever. Antibiotic treatment of streptococcal pharyn-
gitis appears to be an effective health intervention that is
simple to administer; however, its benefits have not been
realised in much of the developing world [1].
Controversy exists over the priority that the primary pre-
vention of rheumatic fever deserves in the competition for
scarce resources for healthcare in developing countries
[1]. In this context it has been argued that secondary
rather than primary prevention should be the mainstay of
community-based approaches to the control of rheumatic
fever and rheumatic heart disease [1]. Unfortunately,
these discussions take place in an information vacuum,
since the benefits of primary prevention of rheumatic
fever, to the best of our knowledge, have not been quanti-
fied in a systematic fashion. This review aims to summa-
rise the evidence on the effectiveness of antibiotics for the
prevention of acute rheumatic fever, and seeks to deter-
mine to what extent the introduction of primary preven-
tion programmes for rheumatic fever is supported by
existing research.
Methods
Study search
We systematically searched the Cochrane Central Register
of Controlled Trials (Cochrane Library Issue 4, 2003),
MEDLINE (1966–2003), EMBASE (1966–2003), and the
reference lists of identified studies. Search terms included:
sore throat, pharyngitis, rheumatic, streptococcal pharyn-
gitis, strep throat, antibiotics, and tonsillitis. We reviewed
the selected titles and abstracts (when available) to iden-
tify which studies were trials. There were no language
restrictions.
Inclusion criteria
We included only randomised and quasi-randomised
controlled trials on a patient population presenting with
a sore throat (pharyngitis) with or without confirmation
of GAS infection by a throat culture and/or a rapid test,
and no history of rheumatic fever. Trials that did not spec-
ify the method of randomisation and for which the
authors were not available for follow-up were excluded.BMC Cardiovascular Disorders 2005, 5:11 http://www.biomedcentral.com/1471-2261/5/11
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Trials were required to use the Jones Criteria for the diag-
nosis of rheumatic fever. A positive diagnosis required the
presence of 2 major criteria [carditis, migrating polyarthri-
tis of the big joints, chorea, erythema marginatum, subcu-
taneous nodules] or 1 major and 2 minor criteria [fever,
arthralgia without arthritis, previous history of RF or
RHD, prolonged P-R interval, elevated erythrocyte sedi-
mentation rate, positive C-reactive protein, leucocytosis]
[15].
Acceptable interventions included any antibiotic versus
placebo or no treatment. Acceptable trials included the
incidence of a first attack of acute rheumatic fever follow-
ing throat infection as an outcome. Secondary outcomes
that were noted but not required included adverse events
to antibiotic use, adherence to antibiotic therapy and
mortality associated with the first attack of rheumatic
fever.
Data extraction
Using a standardized data form, two reviewers (KR, BM)
independently extracted data from each eligible trial. The
methodological quality of the trials was assessed based on
the method of randomisation, concealment of allocation,
blinding and loss to follow-up. Additional data extracted
from each trial included information on the study setting
(i.e.: hospital vs. community-based trials, geographic
location), on the participants (age, presenting complaint),
and on the details of the interventions.
Data analysis
The results from each study were summarised using rela-
tive risk and a 95% confidence interval (CI). The chi-
squared test for heterogeneity was used, along with the
visual inspection of graphs to determine the level of
between study variation. As the p-value associated with
this test was large (>0.10), indicating low-levels of statisti-
cal heterogeneity between study results, a fixed-effect
model was used to pool the data to estimate an overall
effect. A subgroup analysis included only studies where
penicillin was used as the intervention.
Results
Study search
Seventy seven potentially eligible studies were identified
by the preliminary search. Based on their titles and
abstracts (when available), 41 studies were retrieved for a
thorough evaluation, performed independently by two
reviewers (KAR, BMM) (Fig. 1). Discrepancies in the selec-
tion of studies were resolved through discussion. The
reviewers were not blinded to the source, institution or
results of the studies.
Thirty one of 41 studies that were retrieved in full-text
were excluded for the following reasons: rheumatic fever
not included as an outcome (11), not trials (5), no ran-
domisation or method of randomisation not described
(5), trial on secondary prevention of rheumatic fever (3),
control group not used (3), retrospective study (2),
patients included with a history of rheumatic fever (1),
non-human subjects used (1).
Characteristics of included studies
Ten studies were included in the review (Table 1) [16-25].
The studies were all hospital-based, 8 out of 10 of which
were conducted at U.S. military hospitals from 1950 to
1957 [16,18-24]. Only 3 of the studies used placebos for
the control group [20,21,23]. The remainder used either
no treatment or symptomatic treatment as controls.
Patients in the US-based studies comprised males, aged 17
years and older [16,18-24]. One trial included children
aged 3–16 [25], and another involved adults and children
[17]. We sought only studies on patients with no previous
history of rheumatic fever. While 3 of the 10 included
studies reported some patients with a rheumatic fever his-
tory [16,19,22], the rates were below the margin of error
(5.0%) and therefore negligible. All 10 studies made the
attempt to limit the study participants to those with sus-
pected GAS infection, a diagnosis that was based on the
observance of exudate on the tonsils or pharynx in 9 out
of 10 studies. The use of this single criterion for the diag-
nosis of GAS infection was supported by a study estimat-
ing that 70–90% of patients admitted to army hospitals
around the same time period with streptococcal tonsillitis
or pharyngitis presented with exudate on their tonsils or
oropharynx [26].
All 10 studies conducted appropriately timed follow-up
visits at 3–4 weeks following the initial onset of symp-
toms given the 3-week delay in the onset of clinical signs
of rheumatic fever. Adherence to therapy was not meas-
ured in any of the studies, as all of the studies included
were hospital-based and antibiotics were not self-admin-
istered. Approximately half of the studies mentioned side
effects as an outcome; however, most were not quantified.
Symptoms mentioned were pain at the site of injection,
nausea and diarrhea.
The methodological quality of the studies, in general, was
poor. Nine out of the ten studies reviewed date back to the
1950's when randomised trial methods were still evolving
and good guidelines for conducting trials were not yet
available [16-24]. Regarding randomisation and alloca-
tion concealment, two trials used shuffled cards and were
considered to be truly randomised [20,21]. The remaining
studies were categorized as 'quasi-randomised' as alloca-
tion was based on methods such as Air Force Serial
number, and date of hospital admission. As an "open"
system of randomisation was used in all trials, allocation
concealment was deemed inadequate in all cases. ThreeBMC Cardiovascular Disorders 2005, 5:11 http://www.biomedcentral.com/1471-2261/5/11
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out of 10 studies were placebo-controlled [20,22,23],
however, this did not ensure blinding of patients and pro-
viders as the placebo used was not identical in appearance
to the experimental treatment. Four studies employed
blinded assessors during follow-up for the diagnosis of
rheumatic fever [16,18,19,22], 2 did not specify whether
the assessor was blinded [24,25], and 1 used no blinding
[17]. Five out of 10 studies reported on loss to follow-up
[16,17,19,22,25]. Data from these trials on the number of
patients that were randomised which could be included in
the final analysis ranges from 81.8% to 95%.
Quantitative data synthesis
1. Incidence of rheumatic fever
Antibiotics versus control
All 10 studies evaluated the effectiveness of antibiotics in
preventing acute rheumatic fever (n = 7665). Three thou-
sand nine hundred and ninety six (3996) received antibi-
otic treatment and 3669 received either placebo or no
specific treatment. As no statistical heterogeneity was
present (p = 0.28) we pooled the results of the individual
studies using the fixed-effect model. Meta-analysis
revealed a substantial protective effect against the onset of
The QUORUM statement Figure 1
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Table 1: Characteristics of included trials
Study ID Randomisation and 
concealment of 
treatment 
allocation
Participants Intervention Effect size % Randomised 
included in 
analysis
Bennike, 1951 Quasi-randomised; 
Inadequate 
concealment of 
treatment
349 admitted to hospital 
with ordinary acute 
tonsillitis, plegmonous 
tonsillitis or ulcerative 
tonsillitis
1. Penicillin: IM, 300,000 
units/day for 6 days 
(adults)
2. Control – symptomatic 
treatment
Not Estimable 88%
Brink, 1951 Quasi-randomised; 
No concealment of 
treatment
475 males, aged 17–21, 
admitted to U.S. military 
hospital with respiratory 
symptoms or fever with 
exudate on tonsils or 
pharyngeal mucosa
1. Procaine penicillin G: IM 
300,000 units/day for 4 
days
2. Aureomycin: avg. 2 g/day 
orally for 4 days
3. Control – no treatment
RR = 0.29 [0.06,1.46] Unknown
Brock, 1953 Randomised; No 
concealment of 
treatment
349 males admitted to U.S. 
military hospital with 
exudative pharyngitis and 
laboratory-confirmed GAS 
infection
1. Procaine penicillin G: IM 
600,000 units/day for 3 
days
2. Control: IM saline 
placebo, day 1 and day 5
RR = 0.11 [0.00,2.71] Unknown
Brumfitt, 1957 Quasi-randomised; 
No concealment of 
treatment
121 males, aged 18–21, 
admitted to U.S. military 
hospital with sore throat, 
pyrexia and no clinical 
evidence of more 
generalized disease of 
which sore throat may 
have been coincident 
feature
1. Combination of 
procaine penicillin G: IM 
600,000 units/day for 4 
days and crystalline 
penicillin: IM 200,000 units/
day for 4 days
2. Control – symptomatic 
treatment
Not estimable Unknown
Chamovitz, 1954 Quasi-randomised; 
Unknown whether 
treatment allocation 
concealed
241 males admitted to U.S. 
military hospital with 
exudative tonsillitis or 
pharyngitis
1. DBED penicillin: IM 
1,200,000 units
2. Control – IM placebo
RR = 0.17 [0.01,3.41] Unknown
Denny, 1950 Quasi-randomised; 
No concealment of 
treatment
1602 males admitted to 
U.S. military hospital with 
respiratory symptoms and 
observed exudate on the 
tonsils or pharyngeal wall
1. Penicillin G: IM 200,000 
units/day for 3 days of 
300,000 units/day for 4 
days
2. Control: symptomatic 
treatment
RR = 0.12 [0.03,0.50] 81.8%
Denny, 1953 Randomised; 
Unknown whether 
treatment allocation 
concealed
207 males admitted to U.S. 
military hospital with 
suspected streptococcal 
infection based on 
presence of exudate on 
tonsils or pharynx and 
total leukocyte count 
exceeding 10,000
1. Crystalline procaine 
penicillin: IM 600,000 units/
day for 5 days
2. Crystalline aureomycin: 
avg. 2 g/day for 5 days
3. Crystalline terramycin: 
avg. 2 g/day for 5 days
4. Control: oral lactose 
placebo for 5 days
RR = 0.64 [0.06,6.92] Unknown
Houser, 1953 Quasi-randomised; 
No concealment of 
treatment
2044 males, ages 17–21, 
admitted to U.S. military 
hospital with exudative 
lesions on their tonsils or 
pharynx
1. Aureomycin: avg. 2 g/day 
for avg. 5 days
2. Control: no specific 
treatment
RR = 0.63 [0.34,1.17] 88%
Siegel, 1961 Quasi-randomised; 
No concealment of 
treatment
1213 children, aged 3–16, 
with uncomplicated acute 
upper-respiratory tract 
disease and laboratory-
confirmed GAS infection
1. Benzathine penicillin G: 
IM 600,000 units
2. Control: symptomatic 
treatment
RR = 0.20 [0.01,4.14] 95%
Wannamaker, 1951 Quasi-randomised; 
No concealment of 
treatment
2340 males, aged 17–20, 
admitted to U.S. military 
hospital with respiratory 
symptoms and exudative 
lesions on the tonsils or 
oropharynx, or oral temp. 
> 100°F
1. Procaine penicillin G: IM 
various dosages (1,200,000 
over 4 days; 600,000 units 
over 3 days; 600,000 single 
dose)
2. Control: no specific 
treatment
RR = 0.21 [0.09,0.47] 83.3%BMC Cardiovascular Disorders 2005, 5:11 http://www.biomedcentral.com/1471-2261/5/11
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acute rheumatic fever in patients treated with antibiotics
(RR = 0.32; 95% CI = 0.21–0.48) (Fig. 2). Twenty nine of
3996 (0.73%) patients taking an antibiotic, and 89 of
3669 (2.4%) patients receiving no antibiotic developed
acute rheumatic fever 1–2 months following a suspected
streptococcal sore throat infection. These findings suggest
that administering antibiotics to a patient with a sore
throat and symptoms suggestive of GAS infection, who
has no history of rheumatic fever, will reduce his or her
risk of acute rheumatic fever by almost 70%. The number
of patients with suspected GAS throat infection needed to
treat with antibiotics to prevent 1 case of acute rheumatic
fever is 53 (NNT = 53).
Sub-group analysis – intramuscular penicillin versus control
Nine out of ten studies compared the effect of intramus-
cular penicillin versus control for the prevention of acute
rheumatic fever [16-21,23-25]. We found no statistical
heterogeneity (p = 0.86) and conducted a fixed-effect,
meta-analysis revealing an even greater protective effect
against acute rheumatic fever with penicillin than all anti-
biotics combined (RR = 0.20, 95% CI = 0.11–0.36) (Fig.
3). Twelve of 3464 patients (0.35%) treated with penicil-
lin, and 63 of 3238 (2.0%) patients on no antibiotic
developed acute rheumatic fever 1–2 months following a
suspected streptococcal sore throat infection. These results
indicate an 80% reduction in risk of acute rheumatic fever
for patients with sore throat and symptoms suggestive of
GAS infection when treated intramuscularly with penicil-
lin. This sub-group analysis yielded an NNT of 60.
2. Adverse outcomes
Only 4 out of 10 studies reported any adverse outcomes
associated with antibiotic treatment [17,18,20,23]. One
study reported on pain at the site of injection [23], and the
others reported on nausea, vomiting, and diarrhea follow-
ing antibiotic treatments. No study reported mortality
associated with an attack of acute rheumatic fever (Table
1).
Discussion
This systematic review found that antibiotic treatment of
sore throat with accompanying symptoms suggestive of
group A streptococcal (GAS) infection is effective in reduc-
ing the attack rate of acute rheumatic fever by 70%. Intra-
muscular penicillin appears to reduce the attack rate by as
much as 80%. There was one fewer case of acute rheu-
matic fever for every 50–60 patients treated with antibiot-
ics. These findings suggest that antibiotic treatment can be
effective for preventing acute rheumatic fever in a popula-
tion with suspected GAS throat infection.
The treatment of GAS pharyngitis is directed towards erad-
ication of the bacteria from the upper respiratory tract.
The infection can usually be eradicated by a single intra-
muscular injection of benzathine benzylpenicillin or by
10 days' treatment with oral penicillin [1]. While the use
of intramuscular penicillin is supported by clinical trials,
few trials have been done to test the efficacy of the oral
penicillin for preventing acute rheumatic fever [27]. There
is resistance to using intramuscular penicillin in some
developing countries due to the perceived higher risk of
anaphylaxis, the dangers associated with the potential
Forest plot of antibiotic trial effect sizes Figure 2
Forest plot of antibiotic trial effect sizes.BMC Cardiovascular Disorders 2005, 5:11 http://www.biomedcentral.com/1471-2261/5/11
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reuse of needles and the discomfort of intramuscular
injections. Concerns over safety issues have resulted in
government orders prohibiting penicillin injections in
hospitals and clinics [28]. Government regulations in
response to some of these fears are warranted, particularly
in the area of infection control through the prevention of
needle reuse. However, with respect to the dangers of ana-
phylaxis, more than 50 years of experience with penicillin
has shown that, while toxic reactions to intramuscular
penicillin have been reported, severe reactions are exceed-
ingly rare, especially in children. Therefore, when given
under sterile conditions, fear regarding the use of
parenteral penicillin is unwarranted [1].
The challenge for policymakers and clinicians is how best
to apply these findings to a developing country setting
where the risk of rheumatic fever persists. The most evi-
dent hindrance to the generalisability of these findings is
the discrepancy in characteristics of the studied popula-
tion and the population currently at risk for rheumatic
fever. All of the included studies were conducted in a
developed country setting a half century ago, and 8 out of
10 studies included only young adult males in their study
population. Variables such as geographic location and age
will affect the incidence of GAS infection as well as the
attack rate of acute rheumatic fever within a population.
These epidemiological differences across populations will
in turn affect the number of cases needed to treat (NNT)
with antibiotics in order to prevent one case of rheumatic
fever. Unfortunately, trials similar to those included in
this review have not been conducted in developing coun-
tries. However, the strong findings of this review do pro-
vide supportive evidence for the development of primary
prevention programs to decrease the long-term sequelae
associated with GAS pharyngitis in developing countries.
The validity of applying the NNT found in this review to
pediatric populations in developing countries is question-
able due to probable differences in GAS infection rates. In
populations with a high incidence of GAS infection, the
proportion of patients with respiratory symptoms that are
infected with GAS will be higher than in a setting of low
GAS infection incidence. A higher GAS incidence will
yield a lower NNT, under the assumption that antibiotics
provide the same protective effect in both populations. In
the population studied, the proportion of suspected GAS
infections that were true positives was large given the high
specificity of the presence of exudate in the oropharynx
area, estimated at 70–90% [26]. To improve the generalis-
ability of these results to the present developing country
setting, criteria for identifying suspected GAS would need
to exhibit similar levels of specificity.
Identifying true cases of streptococcal pharyngitis is diffi-
cult in a developing country setting where laboratory
confirmation of GAS infection is not readily available.
Therefore there is a need to use a clinical prediction rule
(CPR) for the diagnosis of GAS infection that takes into
account these limitations while at the same time maximiz-
ing both sensitivity and specificity. Several CPR's have
been developed and implemented worldwide for diagnos-
ing streptococcal pharyngitis. A CPR put forth by the
WHO Acute Respiratory Infection (ARI) Guideline sug-
gests that both pharyngeal exudate and an enlarged and
Forest plot of penicillin trial sizes Figure 3
Forest plot of penicillin trial sizes.BMC Cardiovascular Disorders 2005, 5:11 http://www.biomedcentral.com/1471-2261/5/11
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tender cervical node should be present [29]. An evalua-
tion of this CPR in a developing country setting estimated
the sensitivity and specificity of these criteria at 12% and
94% respectively [30]. The high specificity ensures that
suspected GAS cases have a high probability of being true
cases; however, the low sensitivity suggests that many true
cases are not identified. It is at this point that a CPR suita-
ble for a developed country diverges from a CPR suitable
for a developing country where the risk of acute rheumatic
fever is significantly higher.
In developing countries, it is more important to detect
and treat all possible cases of GAS infection than to pre-
vent antibiotic treatment for sore throats not attributable
to GAS infection. Therefore an appropriate CPR for this
setting will have high sensitivity, despite the subsequent
tradeoffs of a lowered specificity. It was found that a
revised version of the WHO CPR that included either the
presence of exudate or enlarged cervical nodes exhibited a
sensitivity and specificity of 84% and 40% respectively
when tested in a developing country setting [30]. It should
be noted that the loss of specificity will lead to an increase
in the NNT. The tradeoffs that exist between a CPR's sen-
sitivity, specificity, and the resulting NNT have implica-
tions for the cost of implementing a primary prevention
program for rheumatic fever.
In the absence of accurate epidemiological data on strep-
tococcal pharyngitis and rheumatic fever for the develop-
ing world, a formal cost-effectiveness analysis of the use of
antibiotics for the primary prevention of rheumatic fever
is not feasible. However, anecdotal evidence exists sup-
porting the cost-effectiveness argument. The cost of one
intramuscular injection of penicillin (1.2 million units) in
South Africa is ~ R5.00. Using the NNT found in this
review, one case of rheumatic fever will be prevented for
every 60 patients receiving one intramuscular injection of
penicillin for the treatment of suspected streptococcal
pharyngitis. Therefore the marginal cost of preventing one
case of rheumatic fever is R300.00, or US$46. A recent
study in Sao Paulo, Brazil estimates the economic burden
associated with rheumatic fever and its long-term seque-
lae in a low-income population to be over US$50 million.
Furthermore, treatment costs for chronic rheumatic
patients were estimated at US$319/patient/year [31].
Comparing these costs with the estimated costs of preven-
tion provides support for the cost-effectiveness of
intramuscular antibiotic treatment. An accurate cost-effec-
tiveness analysis can not yet be done for oral antibiotics
until more conclusive evidence on its efficacy is available.
Intuitively, primary prevention is a more desirable out-
come for the individual as well as the health sector. Pri-
mary prevention decreases the burden placed on patients
and health facilities by decreasing reliance on time- and
resource-intensive secondary prevention programs, the
success of which is entirely dependent on patient compli-
ance. However, secondary prevention programmes are
currently thought to be a more cost-effective approach to
RF/RHD prevention and therefore more deserving of
scarce resources available to communities in poor coun-
tries. This study highlights the lack of reliable data
required to accurately assess the cost-effectiveness of a pri-
mary prevention program. While there is some scattered
data on the prevalence of RHD in developing countries,
additional data on the incidence of RF in these settings as
well as the incidence of GAS infections is still needed. Fur-
thermore, the preliminary cost-analysis put forth by this
study suggesting that primary prevention is likely to be
cost-effective, when considered in light of the favorable
outcome of primary prevention, calls for additional atten-
tion and evaluation. At this point, primary prevention
should not be dismissed.
It is important to note that the results of the included trials
could have been distorted by either selection bias, detec-
tion bias, or both, arising from poor methodological qual-
ity. Few studies were adequately randomised, none used
an appropriate method for concealing allocation, only
four blinded the outcome assessors, and only five com-
mented on subjects lost to follow-up. Empirical evidence
suggests that trials with inadequate or unclear allocation
concealment or lack of blinding, on average, lead to over-
estimation of the effects of interventions [32].
Conclusion
Acute rheumatic fever is common among children living
in poor socioeconomic conditions. The findings of this
review support the notion that antibiotic treatment given
to cases of suspected streptococcal pharyngitis is an effec-
tive and safe option for reducing the complication of
acute rheumatic fever. In other parts of the world the inci-
dence of acute rheumatic fever is so low that the risks of
antibiotic use may outweigh the potential benefits. Evi-
dence is needed concerning the effects of antibiotic ther-
apy for preventing rheumatic fever and rheumatic heart
disease in children living in developing countries. Given
the overwhelmingly positive results in the trials included
in this review, placebo-controlled trials could be consid-
ered unethical. Trials comparing antibiotic types, routes of
administration, and treatment regimens within high-risk
groups, however, should be considered. Additionally, the
collection of baseline epidemiological data on GAS infec-
tions, rheumatic fever, and rheumatic heart disease, and
compliance with existing guidelines [33] is needed at the
country level. Data on the ratio of symptomatic to sub-
clinical cases of GAS pharyngitis is also essential for health
planners to assess the level of prevention that is obtaina-
ble through primary prevention. Together, these data will
enable countries to make more accurate estimates of theBMC Cardiovascular Disorders 2005, 5:11 http://www.biomedcentral.com/1471-2261/5/11
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NNT and to assess the potential impact of both primary
and secondary prevention programs on the health and
economic outcomes associated with rheumatic fever.
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